Evofem Biosciences Inc. (Nasdaq: EVFM) announced on Dec. 22 that it has entered into an agreement with the U.S. Centers for Medicare and Medicaid Services to participate in the Medicaid National Drug Rebate Program, providing access to Phexxi for the Medicaid population effective Jan. 1.
In May, the Food and Drug Administration approved Phexxi, Evofem’s non-hormonal prescription gel, for the prevention of pregnancy.
Medicaid provides health coverage to 69.8 million people in the United States, including approximately 25 million adult women. Medicaid is administered by states, according to federal requirements, where each state can determine specific coverage for Phexxi. Per the terms of the rebate program, states must generally cover a manufacturer’s drugs as of the mandatory effective date.
Evofem Biosciences to Participate in Medicaid National Drug Rebate Program for Phexxi® Effective January 1, 2021
Approximately 25 Million Adult Women Covered by Medicaid
News provided by
Share this article
Share this article
SAN DIEGO, Dec. 22, 2020 /PRNewswire/ Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it has entered into an agreement with the U.S. Centers for Medicare and Medicaid Services (CMS) to participate in the Medicaid National Drug Rebate Program (NDRP), providing access to Contraceptive choice should not be a luxury available to only some women. Every woman deserves to choose the method that is right for her individual health needs and unique circumstances, said Saundra Pelletier, Evofem s Chief Executive Officer. We are proud to participate in the NDRP, ensuring that millions of women across the nation who rely on Medicaid for healthcare coverage have access to Phexxi for hormone free, on-demand contraception.